Cannabis Science Brand Releases Worldwide Growth Guidance For Its Formulations Targeting Critical Ailments

Published on Wednesday, 21 December 2011 10:55 Written by TradersHuddle Staff

COLORADO SPRINGS, Colo.-( Business Wire )-

Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to release its analysis of the worldwide market potential for medical cannabis treatments of critical ailments. There are three main markets for distribution, FDA approved prescriptions, OTC Non-psychoactive Neutroceuticals, and licensed dispensaries in legal Medical Marijuana states (currently 16). The Company has a patient oriented, holistic approach to healing with whole plant cannabis extract formulations. We are dedicated to working with Federal, State, and Local regulatory agencies, as well as similar agencies in other countries such as Health Canada, and other international regulatory bodies.

We know and appreciate the unique ability of pytocannabinoids to holisitcally tap into the human endocannabinoid system and help restore biochemical balance. Currently, we are focused on producing top of the line products for MMJ patients at a state level. Cannabis Science has begun with two extract-based formulations currently released to licensed Colorado patients (Cannabis Science CT-1 and Cannabis Science MT-1, both available through Marisol Therapeutics in Pueblo West, CO, and Cannabis Therapeutics in Colorado Springs, CO). These dispensaries carry our unique formulations that are currently, exclusively available for self-administration by Colorado State licensed medical marijuana patients, especially for those with cancer and other severely debilitating illnesses. We are in serious negotiations to expand this type of operation to other medical marijuana states.

INITIAL MARKET OPPORTUNITIES FOR CANNABIS SCIENCE WHOLE PLANT PHARMACEUTICALS

Aids		$12.6		US$ 12.6 Billion in 2010. TechNavio's analysts forecast the Global HIV Drugs market to reach $15.5 billion by 2014.
Alzheimers		$8.3		The global Alzheimer's disease treatment market was valued at $8.3 billion in 2010 $9.0 billion by 2016.
Anti - Aging		$50.0		Currently topping out around $50 billion a year. Global Anti-Aging Products Market to Reach $291.9 Billion by 2015.
Asthma		$25.0		Overall sales in the asthma and COPD drugs market were worth $25 billion in 2008, and increased to an estimated $26 billion in 2009. By 2014, it is projected to increase to $31 billion, for a 5-year compound annual growth rate (CAGR) of 3.3%.
Arthritis		$35.0		The global market for arthritis drugs was worth $35 billion in 2008.
Autism		$22.0		Antipsychotics are among the biggest selling and most profitable of all drugs, generating $22 billion in global sales in 2008.
Cancer		$75.0		Global sales of cancer drugs will grow at a compounded annual rate of 12 to 15 percent, reaching $75 to $80 billion by 2012.
Chronic Pain Management		$22.0		The global pain market recorded sales of $22.0 billion in 2010, rising at a compound annual growth rate (CAGR) of 8.9%market value is set to contract to $18.7 billion by 2016.
Diabetes		$25.0		In 2009, the diabetes treatment market generated worldwide sales of over $25 billion.
Digestive Diseases		$6.0		The global market for medical enzymes is estimated at $6 billion in 2010. The market is growing at a compounded annual growth rate (CAGR) of 3.9%, to reach $7.2 billion in 2015. Therapeutic enzymes are the biggest segment in terms of revenues generated. This sector was valued at $5.3 billion in 2010 and is expected to increase at a 3.6% compound Enzymes used in molecular research will experience the fastest compound annual growth rate (CAGR), 6.2%, over the study period. This sector was worth $546 million in 2010 and should reach nearly $739 million by 2015. Annual growth rate (CAGR) to reach $6.3 billion in 2015.
Glacoma		$14.0		Over $14 billion in 2009 The global glaucoma pharmaceuticals market is projected to exceed $3.35 billion by 2015.
High Blood Pressure		$25.0		The Prescription drug market for the treatment of Hypertension is to continue to rise in value from the $25 billion market.
Influenza		$28.0		In 2009, the global market for antiviral drugs attained total sales of over $28 billion.
Multiple Sclerosis		$8.0		The multiple sclerosis (MS) treatments market is one of the largest for CNS disorders, with total pharmaceutical revenues of over $8 billion in 2009. Revenues for MS treatments will rise significantly from 2010 to 2025.
PTSD		$72.0		$72 billion from top ten drug sales.

Dr. Robert J. Melamede Ph.D., states, “The actual worldwide market for treating critical ailments with Cannabis Science formulation amounts to trillions of dollars. This number is so high because cannabis-based medicines have been prohibited and discouraged for over 70 years. The explosion of modern scientific inquiry into the uniquely all pervasive endocannabinoid system provides a foundation of peer-reviewed science that can overcome resistance. Congress has an approval rating of less that 10% while over 80% of Americans favor the availability of medical marijuana. Cannabis Science believes that our products will spearhead the solution to the growing healthcare crisis in the US and abroad by their ability to correct endocannabinoid imbalances with holisitc, plant-based medicines.”

FORMULATION REVENUES WILL FALL INTO TWO MAIN CATEGORIES:

1. Licensing by product and by territory/country/continent:

This is common pharmaceutical industry practice. (For example: Otsuka $18 million payment to license for Sativex®) Licensing may be a source of revenue in the first year, but none is projected until the second year.

2. Royalties Payments:

The licensing agreements will lead to royalties on the sales of over-the-counter (dispensary) products in the second year, and prescription products in third and subsequent years. Cannabis Science will also benefit from the cross licensing of products developed by licensees domestically and internationally. Thus, if the licensees develop a product in partnership with Cannabis Science, that product would be marketed in the US by Cannabis Science and its affiliates, while meeting all applicable regulatory guidance.

WHOLE PLANT CANNABIS SCIENCE PHARMACEUTICAL PRODUCTS

1. Psychoactive Medicines (FDA Approved Drugs)

2. Non-psychoactive Neutroceuticals

3. Botanical Medicine

4. Dietary Supplements, i.e. Hemp-Based Foods

5. Skin care products i.e. Topical Lotions, Salves, Balms, Creams

Our efforts are propelled by our enthusiasm that grows as we acquire the anecdotal results that guide us. The first patient who self-administered Cannabis Science formulations had basal cell carcinoma on the face. Three lesions were ultimately successfully treated on this individual. This patient happily did not require any surgery after simple topical treatment with cannabis extracts. Similary, another patient with squamous cell carcinoma is having dramatic results after self-administering our extracts. We expect to have these results documented in the near future.

TARGETED CANNABIS SCIENCE BRAND DELIVERY METHODS

1. Extracts

2. Pills

3. Creams

4. Liquids

5. Strips

6. Lozenges

WHERE DO YOU FIT INTO THE PICTURE?

“Become the change you want to see.” –Gandhi

i.		Analytical Labs
ii.		Horticulture Division
iii.		Pharmaceutical grade medical cannabis grown under stringent quality controls
iv.		Cutting-edge facilities for creating oral and topical medications for various ailments.
v.		Initial clinical trials for FDA approval will target cancer
vi.		State of the art manufacturing facilities for cannabis based extracts and pharmaceutical grade drugs.
vii.		Distribution In-state dispensaries today, national pharmacies tomorrow.

“Invest in Change! The Patient’s Voice for Alternative Medicines the Science for the People that will Change the World! Cannabis Science.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Inc.Robert Kane, 1-561-234-6929Investor Relations Managementinfo@cannabisscience.comwww.cannabisscience.comorDr. Robert J. Melamede, 1-888-889-0888President & This e-mail address is being protected from spambots. You need JavaScript enabled to view it.